Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Zoetis Inc. ZTS

Healthcare  —  Drug Manufacturers Specialty & Generic
71.05 0.78 1.11% as of 25 Sep
Market cap
$29.2B
P/E
11.7×
S&P 500 Member Dividend Champion (10y) Revenue Champion (10y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Zoetis Inc. (ZTS) EV/EBITDA

As of 25 September 2026, Zoetis Inc. (ZTS) trades at a EV/EBITDA of 9.6×. Over the past ten years it has ranged from 9.5× (September 2026) to 39.4× (December 2021); the current reading is higher than 0% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 12.3× and below the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 15.7× (23.16%)
FY2024 20.4× (21.48%)
FY2023 26.0× 18.57%
FY2022 21.9× (41.81%)
FY2021 37.6× 22.00%
FY2020 30.8× 10.83%
FY2019 27.8× 33.13%
FY2018 20.9× 3.29%
FY2017 20.2× 9.10%
FY2016 18.5× (41.79%)

Quarterly

Period EV/EBITDA Change
Jun 2026 9.6× (32.91%)
Mar 2026 14.4× (8.29%)
Dec 2025 15.7× (11.73%)
Sep 2025 17.7× (4.97%)
42 more quarters

Against its own ten years

Low 9.5× High 39.4×
Ten-year median 23.7×
Current reading's percentile 0

EV/EBITDA against peers

Company EV/EBITDA
ZTS Zoetis Inc. 9.6×
TAK Takeda Pharmaceutical Co. compare 10.5×
UTHR United Therapeutics Corporation compare 12.0×
VTRS Viatris Inc. compare 12.2×
HLN Haleon PLC Sponsored ADR compare 12.4×
RDY Dr. Reddy's Laboratories Ltd compare 15.9×
NBIX Neurocrine Biosciences, Inc. compare 16.7×
ELAN Elanco Animal Health Incorporated compare 18.8×
TEVA Teva Pharmaceutical Industries Ltd. compare 23.4×
Drug Manufacturers Specialty & Generic industry median 12.3×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on ZTS